Ovatodiolide targets β -catenin signaling in suppressing tumorigenesis and overcoming drug resistance in renal cell carcinoma

Evidence-based Complementary and Alternative Medicine

Volumn 2013, Issue , 2013, Pages

  Ho, Jar Yi ^a,b   Hsu, Ren Jun ^b   Wu, Chieh Lin ^b   Chang, Wen Liang ^a   Cha, Tai Lung ^a,b   Yu, Dah Shyong ^a,b   Yu, Cheng Ping ^a,b  

^a NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

^b TRI SERVICE GENERAL HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BETA CATENIN; OVATODIOLIDE; SORAFENIB; SUNITINIB; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR 4; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CANCER RESISTANCE; CARCINOGENESIS; CARCINOGENICITY; CELL INVASION; CELL MIGRATION; CELL SURVIVAL; CELL VIABILITY; COMPUTER MODEL; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFECT; DRUG POTENTIATION; EPITHELIUM CELL; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; KIDNEY CARCINOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN STABILITY; SCREENING; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT;

EID: 84879331248     PISSN: 1741427X     EISSN: 17414288     Source Type: Journal    
DOI: 10.1155/2013/161628     Document Type: Article

References (65)

1. Ljungberg B., Campbell S. C., Choi H. Y., Jacqmin D., Lee J. E., Weikert S., Kiemeney L. A., The epidemiology of renal cell carcinoma. European Urology 2011 60 4 615 621 10.1016/j.eururo.2011.06.049
2. Bureau of Health Promotion,. Department of Health, Taiwan, China, 2013, http://www.bhp.doh.gov.tw/BHPnet/English/Class.aspx?Sub=statistics&No= 200705180025
3. Weikert S., Ljungberg B., Contemporary epidemiology of renal cell carcinoma: perspectives of primary prevention. World Journal of Urology 2010 28 3 247 252 2-s2.0-77952879584 10.1007/s00345-010-0555-1
4. Finley D. S., Pantuck A. J., Belldegrun A. S., Tumor biology and prognostic factors in renal cell carcinoma. The Oncologist 2011 16 4 13 2-s2.0-79955845726 10.1634/theoncologist.2011-S2-04
5. Singer E. A., Gupta G. N., Srinivasan R., Targeted therapeutic strategies for the management of renal cell carcinoma. Current Opinion in Oncology 2012 24 3 284 290 10.1097/CCO.0b013e328351c646
6. Eisen T., Sternberg C. N., Robert C., Mulders P., Pyle L., Zbinden S., Izzedine H., Escudier B., Targeted therapies for renal cell carcinoma: review of adverse event management strategies. Journal of the National Cancer Institute 2012 104 2 93 113 10.1093/jnci/djr511
7. EU SmPC,. Nexavar, 2013, http://www.ema.europa.eu/humandocs/Humans/EPAR/ nexavar/nexavar.htm
8. EU SmPC,. Votrient, 2013, http://www.ema.europa.eu/humandocs/Humans/EPAR/ votrient/votrient.htm
9. EU SmPC,. Sutent, 2013, http://www.ema.europa.eu/humandocs/Humans/EPAR/ sutent/sutent.htm
10. EU SmPC,. Torisel, 2013, http://www.ema.europa.eu/humandocs/Humans/EPAR/ torisel/torisel.htm
11. EU SmPC,. Avastin, 2013, http://www.ema.europa.eu/humandocs/Humans/EPAR/ avastin/avastin.htm
12. EU SmPC,. Afinitor, 2013, http://www.ema.europa.eu/humandocs/Humans/EPAR/ afinitor/afinitor.htm
13. Nusse R., Wnt signaling in disease and in development. Cell Research 2005 15 1 28 32 2-s2.0-19644373254 10.1038/sj.cr.7290260
14. Saini S., Majid S., Dahiya R., The complex roles of Wnt antagonists in RCC. Nature Reviews Urology 2011 8 12 690 699
15. Hsu R. J., Ho J. Y., Cha T. L., Yu D. S., Wu C. L., Huang W. P., Chu P., Chen Y. H., Chen J. T., Yu C. P., WNT10A plays an oncogenic role in renal cell carcinoma by activating β -catenin pathway. PLoS ONE 2012 7 10 e47649 10.1371/journal.pone.0047649
16. Bilim V., Kawasaki T., Katagiri A., Wakatsuki S. J., Takahashi K., Tomita Y., Altered expression of β -catenin in renal cell cancer and transitional cell cancer with the absence of β -catenin gene mutations. Clinical Cancer Research 2000 6 2 460 466 2-s2.0-0033974988
17. Klaus A., Birchmeier W., Wnt signalling and its impact on development and cancer. Nature Reviews Cancer 2008 8 5 387 398 2-s2.0-42549164807 10.1038/nrc2389
18. Kim Y. S., Kang Y. K., Kim J. B., Han S. A., Kim K., Paik S. R., β -catenin expression and mutational analysis in renal cell carcinomas. Pathology International 2000 50 9 725 730 2-s2.0-0033780487 10.1046/j.1440-1827.2000. 01111.x
19. Bruder E., Moch H., Ehrlich D., Leuschner I., Harms D., Argani P., Briner J., Graf N., Selle B., Rufle A., Paulussen M., Koesters R., Wnt signaling pathway analysis in renal cell carcinoma in young patients. Modern Pathology 2007 20 12 1217 1229 2-s2.0-36248944140 10.1038/modpathol.3800957
20. Guillén-Ahlers H., Wnt signaling in renal cancer. Current Drug Targets 2008 9 7 591 600 2-s2.0-52449133098 10.2174/138945008784911813
21. Hirata H., Hinoda Y., Nakajima K., Kikuno N., Yamamura S., Kawakami K., Suehiro Y., Tabatabai Z. L., Ishii N., Dahiya R., Wnt antagonist gene polymorphisms and renal cancer. Cancer 2009 115 19 4488 4503 2-s2.0-70349274435 10.1002/cncr.24491
22. Barker N., Clevers H., Mining the Wnt pathway for cancer therapeutics. Nature Reviews Drug Discovery 2006 5 12 997 1014 2-s2.0-33751530490 10.1038/nrd2154
23. Anastas J. N., Moon R. T., WNT signalling pathways as therapeutic targets in cancer. Nature Reviews Cancer 2013 13 1 11 26
24. Majid S., Saini S., Dahiya R., Wnt signaling pathways in urological cancers: past decades and still growing. Molecular Cancer 2012 10 11, article 7
25. Chun G., Lee Y. B., Ann C. H., Abstract #3562: characterization of a novel small molecule with potent anticancer activity. Proceedings of the 101st Annual Meeting of the American Association for Cancer Research (AACR), http://www.rexahn.com/pdf/newwww/AACR%20poster%20RX-8243%20-Final.pdf
26. Fiskus W., Smith J., Mudunuru U., Abstract C144: treatment with β -catenin antagonist BC2059 exhibits single agent efficacy and exerts superior activity with tyrosine kinase inhibitor (TKI) or histone deacetylase (HDAC) inhibitor against human AML, CML, and myeloproliferative neoplasm (MPN) progenitor cells. Molecular Cancer Therapeutics 2011 10 11, supplement 1 C144 10.1158/1535-7163.TARG-11-C144
27. Motzer R. J., Hutson T. E., Tomczak P., Michaelson M. D., Bukowski R. M., Oudard S., Negrier S., Szczylik C., Pili R., Bjarnason G. A., Garcia-del-Muro X., Sosman J. A., Solska E., Wilding G., Thompson J. A., Kim S. T., Chen I., Huang X., Figlin R. A., Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. Journal of Clinical Oncology 2009 27 22 3584 3590 2-s2.0-68949145218 10.1200/JCO.2008.20.1293
28. Sternberg C. N., Davis I. D., Mardiak J., Szczylik C., Lee E., Wagstaff J., Barrios C. H., Salman P., Gladkov O. A., Kavina A., Zarbá J. J., Chen M., McCann L., Pandite L., Roychowdhury D. F., Hawkins R. E., Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. Journal of Clinical Oncology 2010 28 6 1061 1068 2-s2.0-77949890945 10.1200/JCO.2009.23.9764
29. Hudes G., Carducci M., Tomczak P., Dutcher J., Figlin R., Kapoor A., Staroslawska E., Sosman J., McDermott D., Bodrogi I., Kovacevic Z., Lesovoy V., Schmidt-Wolf I. G., Barbarash O., Gokmen E., 'Toole T O., Lustgarten S., Moore L., Motzer R. J., Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. The New England Journal of Medicine 2007 356 22 2271 2281 10.1056/NEJMoa066838
30. Escudier B., Pluzanska A., Koralewski P., Ravaud A., Bracarda S., Szczylik C., Chevreau C., Filipek M., Melichar B., Bajetta E., Gorbunova V., Bay J. O., Bodrogi I., Jagiello-Gruszfeld A., Moore N., Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. The Lancet 2007 370 9605 2103 2111 2-s2.0-37349080670 10.1016/S0140-6736(07)61904-7
31. Rini B. I., Flaherty K., Clinical effect and future considerations for molecularly-targeted therapy in renal cell carcinoma. Urologic Oncology: Seminars and Original Investigations 2008 26 5 543 549 2-s2.0-50649099256 10.1016/j.urolonc.2008.03.012
32. Heng D. Y., Mackenzie M. J., Vaishampayan U., Primary anti-VEGF-refractory metastatic renal cell carcinoma (mRCC): clinical characteristics, risk factors, and subsequent therapy. Proceedings of the American Society of Clinical Oncology Genitourinary Cancers Symposium 2011 abstract no. 305
33. Rao Y. K., Lien H. M., Lin Y. H., Antibacterial activities of Anisomeles indica constituents and their inhibition effect on Helicobacter pylori -induced inflammation in human gastric epithelial cells. Food Chemistry 2012 132 2 780 787 10.1016/j.foodchem.2011.11.037
34. Tang D. Z., Yang F., Yang Z., Huang J., Shi Q., Chen D., Wang Y. J., Psoralen stimulates osteoblast differentiation through activation of BMP signaling. Biochemical and Biophysical Research Communications 2011 405 2 256 261 2-s2.0-79651475048 10.1016/j.bbrc.2011.01.021
35. Waaler J., Machon O., von Kries J. P., Wilson S. R., Lundenes E., Wedlich D., Gradl D., Paulsen J. E., Machonova O., Dembinski J. L., Dinh H., Krauss S., Novel synthetic antagonists of canonical Wnt signaling inhibit colorectal cancer cell growth. Cancer Research 2011 71 1 197 205 2-s2.0-78651385875 10.1158/0008-5472.CAN-10-1282
36. Rödel F., Hoffmann J., Distel L., Herrmann M., Noisternig T., Papadopoulos T., Sauer R., Rödel C., Survivin as a radioresistance factor, and prognostic and therapeutic target for radiotherapy in rectal cancer. Cancer Research 2005 65 11 4881 4887 2-s2.0-19644370614 10.1158/0008-5472.CAN-04-3028
37. Sarthy A. V., Morgan-Lappe S. E., Zakula D., Vernetti L., Schurdak M., Packer J. C. L., Anderson M. G., Shirasawa S., Sasazuki T., Fesik S. W., Survivin depletion preferentially reduces the survival of activated K-Ras-transformed cells. Molecular Cancer Therapeutics 2007 6 1 269 276 2-s2.0-33846846261 10.1158/1535-7163.MCT-06-0560
38. Verheyen E. M., Gottardi C. J., Regulation of Wnt/ β -catenin signaling by protein kinases. Developmental Dynamics 2010 239 1 34 44 2-s2.0-73949093736 10.1002/dvdy.22019
39. Cross D. A. E., Alessi D. R., Cohen P., Andjelkovich M., Hemmings B. A., Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature 1995 378 6559 785 789 2-s2.0-0029587224 10.1038/378785a0
40. Tian Q., Feetham M. C., Tao W. A., He X. C., Li L., Aebersold R., Hood L., Proteomic analysis identifies that 14-3-3 ζ interacts with β -catenin and facilitates its activation by Akt. Proceedings of the National Academy of Sciences of the United States of America 2004 101 43 15370 15375 2-s2.0-7444271412 10.1073/pnas.0406499101
41. Fang D., Hawke D., Zheng Y., Xia Y., Meisenhelder J., Nika H., Mills G. B., Kobayashi R., Hunter T., Lu Z., Phosphorylation of β -catenin by AKT promotes β -catenin transcriptional activity. The Journal of Biological Chemistry 2007 282 15 11221 11229 2-s2.0-34249661591 10.1074/jbc.M611871200
42. Chou T. C., Talalay P., Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Advances in Enzyme Regulation 1984 22 27 55 2-s2.0-0021118703
43. Yang F., van Meter T. E., Buettner R., Hedvat M., Liang W., Kowolik C. M., Mepani N., Mirosevich J., Nam S., Chen M. Y., Tye G., Kirschbaum M., Jove R., Sorafenib inhibits signal transducer and activator of transcription 3 signaling associated with growth arrest and apoptosis of medulloblastomas. Molecular Cancer Therapeutics 2008 7 11 3519 3526 2-s2.0-56249096211 10.1158/1535-7163.MCT-08-0138
44. Rao Y. K., Fang S. H., Hsieh S. C., Yeh T. H., Tzeng Y. M., The constituents of Anisomeles indica and their anti-inflammatory activities. Journal of Ethnopharmacology 2009 121 2 292 296 2-s2.0-57949102365 10.1016/j.jep.2008.10.032
45. Momose Y., Nimura M., Arisawa M., Hayashi T., Takeda R., Nakanishi S., Hypotensive activity of ovatodiolides isolated from a Chinese crude drug 'Fang Feng Cao'. Phytotherapy Research 1994 8 8 482 484 2-s2.0-0028191162
46. Arisawa M., Nimura M., Fujita A., Hayashi T., Morita N., Koshimura S., Biological active macrocyclic diterpenoids from Chinese drug "Fang Feng Cao"; II. Derivatives of ovatodiolids and their cytotoxity. Planta Medica 1986 4 297 299 2-s2.0-0022446644
47. Chen Y. L., Lan Y. H., Hsieh P. W., Wu C. C., Chen S. L., Yen C. T., Chang F. R., Hung W. C., Wu Y. C., Bioactive cembrane diterpenoids of anisomeles indica. Journal of Natural Products 2008 71 7 1207 1212 2-s2.0-49049107730 10.1021/np800147z
48. Hou Y. Y., Wu M. L., Hwang Y. C., Chang F. R., Wu Y. C., Wu C. C., The natural diterpenoid ovatodiolide induces cell cycle arrest and apoptosis in human oral squamous cell carcinoma Ca9-22 cells. Life Sciences 2009 85 1-2 26 32 2-s2.0-67349191872 10.1016/j.lfs.2009.04.013
49. Moon R. T., Kohn A. D., de Ferrari G. V., Kaykas A., WNT and β -catenin signalling: diseases and therapies. Nature Reviews Genetics 2004 5 9 691 701 2-s2.0-4344584730 10.1038/nrg1427
50. Takahashi-Yanaga F., Sasaguri T., The Wnt/ β -catenin signaling pathway as a target in drug discovery. Journal of Pharmacological Sciences 2007 104 4 293 302 2-s2.0-34548513061 10.1254/jphs.CR0070024
51. Ikeda S., Kishida M., Matsuura Y., Usui H., Kikuchi A., GSK-3 β -dependent phosphorylation of adenomatous polyposis cop gene product can be modulated by β -catenin and protein phosphatase 2A complexed with Axin. Oncogene 2000 19 4 537 545 2-s2.0-0034719170
52. Lepourcelet M., Chen Y. N. P., France D. S., Wang H., Crews P., Petersen F., Bruseo C., Wood A. W., Shivdasani R. A., Small-molecule antagonists of the oncogenic Tcf/ β -catenin protein complex. Cancer Cell 2004 5 1 91 102 2-s2.0-1642512639 10.1016/S1535-6108(03)00334-9
53. Wang W., Liu H., Wang S., Hao X., Li L., A diterpenoid derivative 15-oxospiramilactone inhibits Wnt/ Β -catenin signaling and colon cancer cell tumorigenesis. Cell Research 2011 21 5 730 740 2-s2.0-79955613593 10.1038/cr.2011.30
54. Emami K. H., Nguyen C., Ma H., Kim D. H., Jeong K. W., Eguchi M., Moon R. T., Teo J. L., Oh S. W., Kim H. Y., Moon S. H., Hall J. R., Kahn M., A small molecule inhibitor of β -catenin/cyclic AMP response element-binding protein transcription. Proceedings of the National Academy of Sciences of the United States of America 2004 101 34 12682 12687 2-s2.0-4344587136 10.1073/pnas.0404875101
55. Chen B., Dodge M. E., Tang W., Lu J., Ma Z., Fan C. W., Wei S., Hao W., Kilgore J., Williams N. S., Roth M. G., Amatruda J. F., Chen C., Lum L., Small molecule-mediated disruption of Wnt-dependent signaling in tissue regeneration and cancer. Nature Chemical Biology 2009 5 2 100 107 2-s2.0-58249122326 10.1038/nchembio.137
56. Shan J., Shi D. L., Wang J., Zheng J., Identification of a specific inhibitor of the Dishevelled PDZ domain. Biochemistry 2005 44 47 15495 15503 2-s2.0-28244496603 10.1021/bi0512602
57. Mita A. C., Mita M. M., Nawrocki S. T., Giles F. J., Survivin: key regulator of mitosis and apoptosis and novel target for cancer therapeutics. Clinical Cancer Research 2008 14 16 5000 5005 2-s2.0-52649172153 10.1158/1078-0432.CCR-08-0746
58. Olmeda D., Castel S., Vilaró S., Cano A., β -catenin regulation during the cell cycle: implications in G2/M and apoptosis. Molecular Biology of the Cell 2003 14 7 2844 2860 2-s2.0-0038107468 10.1091/mbc.E03-01- 0865
59. Al-Husein B., Abdalla M., Trepte M., Deremer D. L., Somanath P. R., Antiangiogenic therapy for cancer: an update. Pharmacotherapy 2012 32 12 1095 1111 10.1002/phar.1147
60. Rini B. I., Atkins M. B., Resistance to targeted therapy in renal-cell carcinoma. The Lancet Oncology 2009 10 10 992 1000 2-s2.0-70349385645 10.1016/S1470-2045(09)70240-2
61. Zhang L., Bhasin M., Schor-Bardach R., Wang X., Collins M. P., Panka D., Putheti P., Signoretti S., Alsop D. C., Libermann T., Atkins M. B., Mier J. W., Goldberg S. N., Bhatt R. S., Resistance of renal cell carcinoma to sorafenib is mediated by potentially reversible gene expression. PLoS ONE 2011 6 4 2-s2.0-79955705800 10.1371/journal.pone.0019144 e19144
62. Bhatt R. S., Wang X., Zhang L., Collins M. P., Signoretti S., Alsop D. C., Goldberg S. N., Atkins M. B., Mier J. W., Renal cancer resistance to antiangiogenic therapy is delayed by restoration of angiostatic signaling. Molecular Cancer Therapeutics 2010 9 10 2793 2802 2-s2.0-77958072683 10.1158/1535-7163.MCT-10-0477
63. Cho I. C., Chung J., Current status of targeted therapy for advanced renal cell carcinoma. Korean Journal of Urology 2012 53 4 217 228 10.4111/kju.2012.53.4.217
64. Banumathy G., Cairns P., Signaling pathways in renal cell carcinoma. Cancer Biology and Therapy 2010 10 7 658 664 2-s2.0-77957549861 10.4161/cbt.10.7.13247
65. Reagan-Shaw S., Nihal M., Ahmad N., Dose translation from animal to human studies revisited. FASEB Journal 2008 22 3 659 661 2-s2.0-40449086665 10.1096/fj.07-9574LSF